AbbVie sucks
World of DTC Marketing
MARCH 10, 2022
AbbVie’s wall of patents protecting its top-selling drug Humira will keep another would-be competitor from entering the U.S. market until next year, with the pharmaceutical company announcing Tuesday a settlement with the Iceland-based Alvotech. Sales of Humira earned AbbVie $20.7 billion last year, the highest total for any pharmaceutical product and they will do anything to keep that money.
Let's personalize your content